Crestone, Inc. joins the Antimicrobials Working Group
June 8, 2021 – Announcement: Crestone, Inc. joins the Antimicrobials Working Group to Combat...Read More
First Patient Enrolled in Phase 2 Clinical Trial + QIDP & Fast Track
June 7, 2021 – Announcement: Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial...Read More
Funding Secured for Development Through Phase 1: CRS0540
July 1, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Development Through...Read More
Grant Received from State of Colorado Advanced Industries Accelerator
May 29, 2020 – Announcement: Crestone, Inc. receives $250,000 Grant from State of Colorado...Read More
NIH Funding Secured for Preclinical Development of CRS3123
Apr 27, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Preclinical Development...Read More
Funding: Preclinical Development of Novel Antibiotic for NTM Infection
CFF Funding Secured Crestone, Inc. (Boulder) Secures CFF Funding for Preclinical Development of...Read More
NIH Funding Secured for Phase 2 Clinical Trial of CRS3123
Sep 12, 2019 – Announcement: Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial...Read More
Research Agreement with Colorado University at Boulder
Dec 20, 2017 – Announcement: Crestone enters a Research Agreement with Colorado University...Read More
Crestone Awarded a Phase II SBIR Grant
Phase II SBIR Grant: “Optimization and Lead Selection of Novel Antimycobacterial Agents” InfoData...Read More
Crestone Sponsors Peggy Lillis Foundation FIGHT C. DIFF. Gala
Sponsor Details Crestone is proud to be a sponsor of the Peggy Lillis Foundation FIGHT C. DIFF....
Become a Part of Our Projects
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor, a team member, or a participant in our ongoing clinical studies.
Have a question or comment? Follow the link below to contact us about general inquiries.
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
Learn how you can become part of our ongoing clinical study to fight deadly GI tract infections.